NervGen Pharma CFO Bill Adams to Retire March 15, 2026; Search Launched
NervGen Pharma’s CFO Bill Adams will retire on March 15, 2026, after six years guiding the company from preclinical stage to a Nasdaq listing. The company has engaged an executive search firm to appoint a successor and Adams will remain in an advisory role supporting late-stage development of NVG-291.
1. CFO Retirement and Effective Date
Bill Adams, who has served as NervGen Pharma’s Chief Financial Officer for six years, will retire effective March 15, 2026. His departure marks the end of a tenure that saw the company evolve from preclinical research into a Nasdaq-listed clinical-stage biopharmaceutical firm.
2. Succession Planning
NervGen has retained a leading executive search firm to identify and recruit Adams’s successor. Adams will provide advisory support post-retirement to ensure continuity in financial leadership and oversight of ongoing programs.
3. Adams’s Contributions
During his tenure, Adams oversaw the company’s financial strategy through preclinical and first-in-human studies and supported its Nasdaq listing. His leadership helped position NVG-291 for late-stage clinical development with Fast Track and Orphan Drug designations.